Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKIPPAIN: Speed of onset of secukinumab-induced relief from pain in axial spondyloarthritis
2017-000401-21Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in axial spondyloarthritis (axSpA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) comparing Secukinumab 150 mg with Placebo (2 arms). Primary endpoint: Spinal pain response at Week 8. Started Apr 2017; status: completed.
02
Drugs
secukinumab
03
Conditions
axial spondyloarthritis (axSpA)ankylosing spondylitis (AS)non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on 2017-000401-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000401-21.